Paget's disease of the breast medical therapy: Difference between revisions
Preeti Singh (talk | contribs) |
Preeti Singh (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
=== Non-operative management=== | === Non-operative management=== | ||
*The mainstay of therapies for Paget's disease of the breast are divided into 2 groups: hormonal therapy and targeted therapy.<ref name="pmid12115309">{{cite journal |vauthors=Kothari AS, Beechey-Newman N, Hamed H, Fentiman IS, D'Arrigo C, Hanby AM, Ryder K |title=Paget disease of the nipple: a multifocal manifestation of higher-risk disease |journal=Cancer |volume=95 |issue=1 |pages=1–7 |date=July 2002 |pmid=12115309 |doi=10.1002/cncr.10638 |url=}}</ref><ref name="pmid20071685">{{cite journal |vauthors=Virnig BA, Tuttle TM, Shamliyan T, Kane RL |title=Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes |journal=J. Natl. Cancer Inst. |volume=102 |issue=3 |pages=170–8 |year=2010 |pmid=20071685 |doi=10.1093/jnci/djp482 |url=}}</ref> | *The mainstay of therapies for Paget's disease of the breast are divided into 2 groups: hormonal therapy and targeted therapy. | ||
*The primary goal of medical therapy is to reduce the risk of ipsilateral or contralateral breast invasion and also decreases the risk of recurrence.<ref name="pmid12115309">{{cite journal |vauthors=Kothari AS, Beechey-Newman N, Hamed H, Fentiman IS, D'Arrigo C, Hanby AM, Ryder K |title=Paget disease of the nipple: a multifocal manifestation of higher-risk disease |journal=Cancer |volume=95 |issue=1 |pages=1–7 |date=July 2002 |pmid=12115309 |doi=10.1002/cncr.10638 |url=}}</ref><ref name="pmid26770622">{{cite journal |vauthors=Song Q, Jin Y, Huang T, Zhang JH |title=Diagnosis and treatment of Paget's disease of the breast: an analysis of 72 cases |journal=Int J Clin Exp Med |volume=8 |issue=10 |pages=19616–20 |date=2015 |pmid=26770622 |pmc=4694522 |doi= |url=}}</ref><ref name="pmid20071685">{{cite journal |vauthors=Virnig BA, Tuttle TM, Shamliyan T, Kane RL |title=Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes |journal=J. Natl. Cancer Inst. |volume=102 |issue=3 |pages=170–8 |year=2010 |pmid=20071685 |doi=10.1093/jnci/djp482 |url=}}</ref> | |||
'''Hormonal Therapy''' | '''Hormonal Therapy''' | ||
*Selective estrogen receptor modulators, such as: | |||
*[[Tamoxifen]] | |||
*[[Raloxifene]] | |||
'''Targeted Therapy''' | '''Targeted Therapy''' | ||
*HER2-directed therapy | |||
*[[Trastuzumab]] | |||
==References== | ==References== | ||
Revision as of 17:29, 7 February 2019
|
Paget's disease of the breast Microchapters |
|
Differentiating Paget's disease of the breast from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Paget's disease of the breast medical therapy On the Web |
|
American Roentgen Ray Society Images of Paget's disease of the breast medical therapy |
|
Directions to Hospitals Treating Paget's disease of the breast |
|
Risk calculators and risk factors for Paget's disease of the breast medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Overview
Chemotherapy and radiotherapy are indicated for Paget's disease of the breast as adjuvant therapy or palliative treatment in patients with underlying ductal carcinoma or invasive breast cancer. Surgery is the mainstay of treatment for Paget's disease of the breast.
Medical Therapy
The mainstay of treatment for Paget's disease of the breast is surgery. Non-operative management is reserved for a very small proportion of patients.
Non-operative management
- The mainstay of therapies for Paget's disease of the breast are divided into 2 groups: hormonal therapy and targeted therapy.
- The primary goal of medical therapy is to reduce the risk of ipsilateral or contralateral breast invasion and also decreases the risk of recurrence.[1][2][3]
Hormonal Therapy
- Selective estrogen receptor modulators, such as:
- Tamoxifen
- Raloxifene
Targeted Therapy
- HER2-directed therapy
- Trastuzumab
References
- ↑ Kothari AS, Beechey-Newman N, Hamed H, Fentiman IS, D'Arrigo C, Hanby AM, Ryder K (July 2002). "Paget disease of the nipple: a multifocal manifestation of higher-risk disease". Cancer. 95 (1): 1–7. doi:10.1002/cncr.10638. PMID 12115309.
- ↑ Song Q, Jin Y, Huang T, Zhang JH (2015). "Diagnosis and treatment of Paget's disease of the breast: an analysis of 72 cases". Int J Clin Exp Med. 8 (10): 19616–20. PMC 4694522. PMID 26770622.
- ↑ Virnig BA, Tuttle TM, Shamliyan T, Kane RL (2010). "Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes". J. Natl. Cancer Inst. 102 (3): 170–8. doi:10.1093/jnci/djp482. PMID 20071685.